Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.12 USD | -2.08% | -26.39% | -63.00% |
Jun. 04 | US Equities Markets Close Mixed Monday as US Manufacturing Contracts | MT |
Jun. 04 | HC Wainwright Adjusts Price Target on Caribou Biosciences to $9 From $24, Maintains Buy Rating | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-63.00% | 196M | C | ||
+55.70% | 55.7B | B- | ||
+41.08% | 39.91B | A | ||
-5.39% | 39.57B | B | ||
-5.56% | 28.16B | C | ||
+16.46% | 26.3B | B- | ||
-20.56% | 18.94B | B | ||
+33.03% | 12.17B | C+ | ||
+25.85% | 12.12B | B+ | ||
+2.72% | 12.12B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CRBU Stock
- Ratings Caribou Biosciences, Inc.